Colombo AV, Sadler RK, Llovera G, Singh V, Roth S, Heindl S, Sebastian Monasor L, Verhoeven A, Peters F, Parhizkar S, Kamp F, de Gomez Aguero M, MacPherson AJ, Winkler E, Herms J, Benakis C, Dichgans M, Steiner H, Giera M, Haass C, Tahirovic S, Liesz A (2021) Microbiota-derived short chain fatty acids modulate microglia and promote A plaque deposition
It is important to understand that compounded tirzepatide products have not undergone the extensive testing required for FDA approval like Zepbound and Mounjaro have
However, a fear has recently emerged that oral GLP-1 analogs will cannibalize the market share of injectables
PwC reports that the next segment of the obesity drug market will most likely be characterized by expanded indications, more patient-friendly delivery formats and therapies with stronger adherence profiles
19-26, 10.1254/jphs.95.19 7